Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5) is an enzyme that catalyzes the hydrolysis of cGMP to 5'-GMP. It plays a crucial role in regulating intracellular cGMP concentrations, modulating signal transduction pathways involved in smooth muscle relaxation and other physiological processes. PDE5 is a therapeutic target for erectile dysfunction and pulmonary hypertension, with inhibitors like sildenafil, tadalafil, and vardenafil used to increase cGMP levels and promote vasodilation.
Selective inhibition of PDE5, increasing cGMP levels and promoting smooth muscle relaxation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5).